Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients

Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients

Authors: Perez Ruixo JJ, Zannikos P, Hirankarn S, Stuyckens K, Ludwig EA, Soto-Matos A, Lopez-Lazaro L, Owen JS
Publication: Clin Pharmacokinet
Keywords: 80 and over, administration & dosage, adult, aged, analysis, antineoplastic agents, area under curve, bilirubin, Creatinine, Dioxoles, drug therapy, female, half-life, humans, infusions, intravenous, male, metabolism, methods, middle-aged, models
Division: Clinical Pharmacology and Pharmacometrics (CPP)

To characterise the population pharmacokinetics of trabectedin (ET-743, Yondelis(R)) in cancer patients.

Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma

Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma

Authors: Maier G, Rubino C, Hsu R, Grasela TH, Baumgartner RA
Publication: Pulm Pharmacol Ther
Keywords: aged, analysis, Asthma, blood, metabolism, methods, pediatrics, pharmacokinetics, pharmacology, population
Division: Clinical Pharmacology and Pharmacometrics (CPP)

To characterize the population pharmacokinetics (PK) of (R)- and (S)-albuterol in pediatric asthmatics using a model that supports a sparse blood sampling strategy.

Targeting Plague Virulence Factors: A Combined Machine Learning Method and Multiple Conformational Virtual Screening for the Discovery of Yersinia Protein Kinase A Inhibitors

Targeting Plague Virulence Factors: A Combined Machine Learning Method and Multiple Conformational Virtual Screening for the Discovery of Yersinia Protein Kinase A Inhibitors

Authors: Hu X, Prehna G, Stebbins CE
Publication: J Med Chem
Keywords: anti-plague drugs, high-throughput docking, machine learning method, Yersinia protein kinase A (YpkA)
Software: ADMET Predictor®

Yersinia spp. is currently an antibiotic resistance concern and a re-emerging disease.

Pharmacometrics and the transition to model-based development

Pharmacometrics and the transition to model-based development

Keywords: analysis, animals, clinical, computer simulation, data_assembly_and_programming, Drug Approval, drug design, Drug Information Services, humans, methods, models, New York, pharmacology, statistics & numerical data, Theoretical
Division: Clinical Pharmacology and Pharmacometrics (CPP)

As the transition to model-based drug development continues, pharmacometric analysis will have an increasingly important role across the entire life cycle of drug discovery...

Effect of Formulation on Adinazolam Pharmacokinetics and Pharmacodynamics

Effect of Formulation on Adinazolam Pharmacokinetics and Pharmacodynamics

Authors: Lukacova V, Fraczkiewicz G, Prabhakaran A, Bolger MB, Woltosz WS
Conference: CRS
Keywords: Adinazolam, controlled release, dissolution testing, oral, oral dose, PD, pharmacodynamics (PD), pharmacokinetics (PK), PK
Software: DDDPlus™, GastroPlus®
Division: PBPK

Adinazolam has been reported to have anxiolytic and antidepressant properties [1]. Numerous pharmacokinetic (PK) and pharmacodynamic (PD) studies of immediate release as well as sustained release…

Designing In Vitro Dissolution Tests to Better Mimic In Vivo Release

Designing In Vitro Dissolution Tests to Better Mimic In Vivo Release

Authors: Woltosz WS, Lukacova V, Prabhakaran A, DiBella J, Bolger MB
Conference: CRS
Keywords: absorption, controlled release, Cp-Time, dissolution, dissolution testing, metabolism, USP
Software: DDDPlus™, GastroPlus®
Division: PBPK

In vitro dissolution tests were traditionally designed for quality control. USP methods commonly used to evaluate the release rate of new controlled release dosage forms are often based on such experiments.

Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus

Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus

Authors: He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, Holst JJ, Schwartz S, Nielsen JC, Ligueros-Saylan M
Publication: Clin Pharmacokinet
Keywords: Adamantane, administration, administration & dosage, adult, adverse effects, aged, analogs & derivatives, area under curve, blood, Blood Glucose, chemically induced, cross-over studies, diabetes mellitus, Dose-Response Relationship, Doubl, drug, oral, type 2
Division: Clinical Pharmacology and Pharmacometrics (CPP)

Vildagliptin is a dipeptidyl peptidase IV (DPP-4) inhibitor currently under development for the treatment of type 2 diabetes mellitus.